Physical stability comparisons of IgG1-Fc variants: Effects of N-glycosylation site occupancy and Asp/gln residues at site asn 297

Journal of Pharmaceutical Sciences

Volumn 103, Issue 6, 2014, Pages 1613-1627

  Alsenaidy, Mohammad A ^a   Okbazghi, Solomon Z ^a   Kim, Jae Hyun ^a   Joshi, Sangeeta B ^a   Russell Middaugh, C ^a   Tolbert, Thomas J ^a   Volkin, David B ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

conformation; Fc; formulation; glycosylation; IgG; mass spectrometry; monoclonal antibody; spectroscopy; stability

Indexed keywords

ASPARAGINE; ASPARTIC ACID; GLUTAMINE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; PROTEIN VARIANT; GLYCINE; IMMUNOGLOBULIN G;

AMINO ACID SUBSTITUTION; ARTICLE; COMPARATIVE STUDY; DEGLYCOSYLATION; ELECTROSPRAY MASS SPECTROMETRY; ENVIRONMENTAL TEMPERATURE; FLUORESCENCE SPECTROSCOPY; GEL PERMEATION CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; NONHUMAN; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING; CHEMISTRY; GEL CHROMATOGRAPHY; GLYCOSYLATION; ULTRAVIOLET SPECTROPHOTOMETRY;

ASPARAGINE; BLOTTING, WESTERN; CHROMATOGRAPHY, GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLYCINE; GLYCOSYLATION; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84901271614     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23975     Document Type: Article

References (46)

1. Aggarwal SR,. 2012. What's fueling the biotech engine-2011 to 2012. Nat Biotechnol 30: 1191-1197.
2. Reichert JM,. 2013. Antibodies to watch in 2013: Mid-year update. mAbs 5 (4): 0-1.
3. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA,. 2007. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25 (1): 21-50.
4. Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G,. 2012. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem Biol 7 (9): 1596-1602.
5. Li CH, Narhi LO, Wen J, Dimitrova M, Wen Z-Q, Li J, Pollastrini J, Nguyen XC, Tsuruda T, Jiang Y,. 2012. The effect of pH, temperature and salt on the stability of E. Coli and CHO derived IgG1 Fc. Biochemistry 51 (50): 10056-10065.
6. Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL,. 2011. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J 6 (1): 38-44.
7. Wang W, Antonsen K, Wang YJ, Wang DQ,. 2008. pH dependent effect of glycosylation on protein stability. Eur J Pharm Sci 33 (2): 120-127.
8. Latypov RF, Hogan S, Lau H, Gadgil H, Liu D,. 2012. Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. J Biol Chem 287 (2): 1381-1396.
9. Liu L, Stadheim A, Hamuro L, Pittman T, Wang W, Zha D, Hochman J, Prueksaritanont T,. 2011. Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: A comparative study with CHO produced materials. Biologicals 39 (4): 205-210.
10. Raju TS, Scallon BJ,. 2006. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem Biophys Res Commun 341 (3): 797-803.
11. Raju TS, Briggs JB, Chamow SM, Winkler ME, Jones AJS,. 2001. Glycoengineering of therapeutic glycoproteins: In vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. Biochemistry 40 (30): 8868-8876.
12. Leymarie N, Zaia J,. 2012. Effective use of mass spectrometry for glycan and glycopeptide structural analysis. Anal Chem 84 (7): 3040-3048.
13. Zauner G, Selman MHJ, Bondt A, Rombouts Y, Blank D, Deelder AM, Wuhrer M,. 2013. Glycoproteomic analysis of antibodies. Mol Cell Proteomics 12 (4): 856-865.
14. Sinha S, Pipes G, Topp EM, Bondarenko PV, Treuheit MJ, Gadgil HS,. 2008. Comparison of LC and LC/MS methods for quantifying N-glycosylation in recombinant IgGs. J Am Soc Mass Spectrom 19 (11): 1643-1654.
15. Wuhrer M,. 2013. Glycomics using mass spectrometry. Glycoconj J 30 (1): 11-22.
16. Bakovic̈ MP, Selman MHJ, Hoffmann M, Rudan I, Campbell H, Deelder AM, Lauc G, Wuhrer M,. 2013. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res 12 (2): 821-831.
17. Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M,. 2013. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 27 (5): 495-507.
18. Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang Y.-MC,. 2010. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 28 (10): 509-516.
19. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC,. 2011. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 21 (7): 949-959.
20. Lu Y, Westland K, Ma Y.-h., Gadgil H,. 2012. Evaluation of effects of Fc domain high-mannose glycan on antibody stability. J Pharm Sci 101 (11): 4107-4117.
21. Labeta MO, Margni RA, Leoni J, Binaghi RA,. 1986. Structure of asymmetric non-precipitating antibody: Presence of a carbohydrate residue in only one Fab region of the molecule. Immunology 57: 311-317.
22. Ha S, Ou Y, Vlasak J, Li Y, Wang S, Vo K, Du Y, Mach A, Fang Y, Zhang N,. 2011. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. Glycobiology 21 (8): 1087-1096.
23. Alsenaidy MA, Wang T, Kim JH, Joshi SB, Lee J, Blaber M, Volkin DB, Middaugh CR,. 2012. An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1. Protein Sci 21 (3): 418-432.
24. Alsenaidy MA, Kim JH, Majumdar R, Weis DD, Joshi SB, Tolbert TJ, Middaugh CR, Volkin DB,. 2013. High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation. J Pharm Sci 102 (11): 3942-3956.
25. Iyer V, Maddux N, Hu L, Cheng W, Youssef AK, Winter G, Joshi SB, Volkin DB, Middaugh CR,. 2013. Comparative signature diagrams to evaluate biophysical data for differences in protein structure across various formulations. J Pharm Sci 102 (1): 43-51.
26. Xiao J, Chen R, Pawlicki MA, Tolbert TJ,. 2009. Targeting a homogeneously glycosylated antibody Fc to bind cancer cells using a synthetic receptor ligand. J Am Chem Soc 131 (38): 13616-13618.
27. Wang S, Ionescu R, Peekhaus N, Leung J.-y., Ha S, Vlasak J,. 2010. Separation of post-translational modifications in monoclonal antibodies by exploiting subtle conformational changes under mildly acidic conditions. J Chromatogr A 1217 (42): 6496-6502.
28. Loo T, Patchett ML, Norris GE, Lott JS,. 2002. Using secretion to solve a solubility problem: High-yield expression in E scherichia coli and purification of the bacterial glycoamidase PNGase F. Protein Expr Purif 24 (1): 90-98.
29. Koene HR, Kleijer M, Algra J, Roos D, E.G.Kr. von dem Borne A, de Haas M,. 1997. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood 90 (3): 1109-1114.
30. Rasband WS,. 1997-2014. ImageJ US, National Institutes of Health, Bethesda, Maryland. accessed April, 2014. http://imagej.nih.gov/ij/.
31. Schneider CA, Rasband WS, Elicieri KW,. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods, 9 (7): 671-675.
32. Bond MD, Panek ME, Zhang Z, Wang D, Mehndiratta P, Zhao H, Gunton K, Ni A, Nedved ML, Burman S, Volkin DB,. 2010. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody. J Pharm Sci 99 (6): 2582-2597.
33. Kim JH, Iyer V, Joshi SB, Volkin DB, Middaugh CR,. 2012. Improved data visualization techniques for analyzing macromolecule structural changes. Protein Sci 21 (10): 1540-1553.
34. Jefferis R,. 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8 (3): 226-234.
35. Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, Umana P, Benz J,. 2011. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA 108 (31): 12669-12674.
36. Federici M, Lubiniecki A, Manikwar P, Volkin DB,. 2013. Analytical lessons learned from selected therapeutic protein drug comparability studies. Biologicals 41 (3): 131-147.
37. Lubiniecki A, Volkin DB, Federici M, Bond MD, Nedved ML, Hendricks L, Mehndiratta P, Bruner M, Burman S, DalMonte P, Kline J, Ni A, Panek ME, Pikounis B, Powers G, Vafa O, Siegel R,. 2011. Comparability assessments of process and product changes made during development of two different monoclonal antibodies. Biologicals 39 (1): 9-22.
38. Amezcua CA, Szabo CM,. 2013. Assessment of higher order structure comparability in therapeutic proteins using nuclear magnetic resonance spectroscopy. J Pharm Sci 102 (6): 1724-1733.
39. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB,. 2012. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 11 (7): 527-540.
40. Houde D, Arndt J, Domeier W, Berkowitz S, Engen JR,. 2009. Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry. Anal Chem 81 (7): 2644-2651.
41. Houde D, Peng Y, Berkowitz SA, Engen JR,. 2010. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 9 (8): 1716-1728.
42. Manikwar P, Majumdar R, Hickey JM, Thakkar SV, Samra HS, Sathish HA, Bishop SM, Middaugh CR, Weis DD, Volkin DB,. 2013. Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/deuterium-exchange mass spectrometry. J Pharm Sci 102 (7): 2136-2151.
43. Majumdar R, Manikwar P, Hickey JM, Samra HS, Sathish HA, Bishop SM, Middaugh CR, Volkin DB, Weis DD,. 2013. Effects of salts from the Hofmeister series on the conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal antibody. Biochemistry 52 (19): 3376-3389.
44. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar DB, Nijem I, Allison DE, Wong PY, Kao Y.-H., Quan C, Joshi A, Harris RJ, Motchnik P,. 2010. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs 2 (6): 613-624.
45. Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, Klinguer-Hamour C, Kirchmeier M, Corvaïa N, Ionescu R, Beck A,. 2009. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem 392 (2): 145-154.
46. Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ,. 2012. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol Pharm 9 (4): 791-802.